Innoviva - 21 Year Stock Split History | INVA

Stock split history for Innoviva since 2004. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.311B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $725.814B 55.66
Johnson & Johnson (JNJ) United States $368.659B 15.25
AbbVie (ABBV) United States $330.918B 18.24
Roche Holding AG (RHHBY) Switzerland $260.220B 0.00
Novartis AG (NVS) Switzerland $247.027B 14.11
Merck (MRK) United States $196.538B 10.05
Pfizer (PFE) United States $132.981B 7.29
Sanofi (SNY) France $121.397B 11.96
Bayer (BAYRY) Germany $28.333B 5.77
Novo Nordisk (NVO) Denmark $0.000B 21.31